Kidney International Reports · Nov 2026
Chronic Kidney Disease Surveillance in a Panamanian Laboratory Cohort
By Courville K, Lezcano J, Bustamante N et al.
Introduction Estimating chronic kidney disease (CKD) burden in Latin America is hindered by fragmented health systems. This study utilizes a national laboratory database for diagnostic surveillance of CKD, identifying screening gaps and regional detection challenges rather than population prevalence. Methods We conducted a retrospective, cross-sectional analysis of secondary laboratory data from adults aged ≥18 years accessing the Panamanian Social Security Fund network (January 1, 2022–January 1, 2024). The dual-marker cohort included adults with concurrent serum creatinine and valid albuminuria/ACR data. CKD was defined using strict laboratory chronicity criteria requiring documented persistence over ≥90 days. Results Among 1,011,004 eligible adults, 98,165 formed the dual-marker analytic cohort. Of these, 11,640 (11.86%) met strict CKD criteria. An elevated A2/A3 result was observed in 29,443 individuals (29.99%), whereas strict persistent A2/A3 albuminuria was confirmed in 4,562 (4.65%). Complete HbA1c, minimum eGFR, age, and sex data were available for 51,968 individuals; each 1% increase in mean HbA1c was associated with a 0.26 mL/min/1.73 m² lower minimum eGFR after adjustment (β=-0.26; 95% CI, -0.37 to -0.14; p<0.001). Conclusions This study highlights a substantial institutional CKD burden among tested patients and reveals a major testing gap: only 10.82% of eligible adults had an albuminuria/ACR test and only 9.71% received complete dual-marker evaluation.